- Undergraduate
Bachelor's Degrees
Bachelor of ArtsBachelor of EngineeringDual-Degree ProgramUndergraduate AdmissionsUndergraduate Experience
- Graduate
Graduate Experience
- Research
- Entrepreneurship
- Community
- About
-
Search
Research Interests
Protein engineering; glycoprotein engineering; high cell density fermentation technology; metabolic engineering; protein expression
Education
- BS/MS, Chemical Engineering, Technical University of Vienna, Austria 1989
- PhD, Molecular Biology, Technical University of Vienna, Austria 1991
Awards
- National Academy of Engineering (NAE) Member, 2017
Startups
Research Projects
-
Glyco-engineering of proteins
Glyco-engineering of proteins
Glyco-engineering of proteins is being developed as a method to control the composition of glycans on glycoproteins. Such methods are of great importance in the biopharmaceutical industry because glyocoproteins constitute over 60% of all approved therapeutic proteins; and the therapeutic properties of many glycoproteins strongly depend on the composition of their glycans.
-
Humanization of glycosylation in yeast
Humanization of glycosylation in yeast
Humanization of glycosylation in yeast enables the use of yeast-based protein expression systems which offer inherent advantages over conventional mammalian cell culture. By engineering yeast-based systems to perform human-like glycosylation fully-humanized therapeutic proteins can be produced in these glyco-engineered hosts.
-
Novel protein expression systems
Novel protein expression systems
Novel protein expression systems are being developed based on the soil bacterium Ralstonia eutropha as an alternative to E.coli-based protein expression. This bacterial host can be grown to cell densities in excess of 150g/l in ultra high cell density culture and allow for the recovery of proteins that are prone to inclusion body formation in E.coli. Specific model proteins have been expressed at levels 100 fold higher than in E.coli thereby providing the impetus for further developing Ralstonia eutropha for the production of therapeutic proteins including monoclonal antibodies and peptides.
-
Cellular engineering of protein expression hosts
Cellular engineering of protein expression hosts
Cellular engineering of protein expression hosts provides the ability to modify proteins in a site specific and controlled fashion—something increasingly important for the development of therapeutic proteins. We are developing methods by which cells are genetically engineered to incorporate sugars on a recombinant protein in a site-specific sequence dependent manner. Once a sugar is positioned on a given protein, conventional chemical modification such as PEGlylation can be used to further modify the protein and improve its therapeutic properties.
-
Cell-based protein purification systems
Cell-based protein purification systems
Cell-based protein purification systems offer advantages over conventional protein purification approaches which rely mostly on chromatographic methods to stepwise enrich for a desired protein of interest. We are developing approaches by which cells are engineered to produce their own affinity matrix to selectively sequester a desired recombinant protein. This allows for the expression and affinity purification of desired proteins in a single host, thereby obviating the need for external chromatographic purification.
-
Fermentation processes
Fermentation processes
Fermentation processes with high cell densities are important for the production of most bio-therapeutics which is conducted in highly controlled fed-batch processes. Commercial yeast- and E.coli-based fermentation processes often reach cell-densities in excess of 50g/l in fed-batch culture. Our laboratory has developed processes for the high cell density cultivation of Ralstonia eutropha allowing us to reach cell densities of over 150g/l and the expression of recombinant proteins at titers exceeding 10g/l. Much of this is achieved by implementing computer controlled feeding algorithms.
Selected Publications
- Gerngross, T.U. It's the problem, stupid! Nature Biotechnology, 30, 742–744 (2012) (Full Text Version)
- Hamilton, S.R., R.C. Davidson, N. Sethuraman, J.H. Nett, Y. Jiang, S. Rios, P. Bobrowicz, T.A. Stadheim, H. Li, B-K. Choi, D. Hopkins, H. Wischnewski, J. Roser, T. Mitchell, R.R. Strawbridge, J. Hoopes, S. Wildt, T.U. Gerngross. Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins. Science, 313(5792):1441-1443 (2006) (Abstract, Full Text Version)
- Li, H., N. Sethuraman, T.A. Stadheim, D. Zha, B. Prinz, N. Ballew, P. Bobrowicz, B-K. Choi, W.J. Cook, M. Cukan, N.R. Houston-Cummings, R. Davidson, B. Gong, S.R. Hamilton, J.P. Hoopes, Y. Jiang, N. Kim, R. Mansfield, J.H. Nett, S. Rios, R.l. Strawbridge, S. Wildt, T.U. Gerngross. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnology. 24, 210 - 215 (2006)
- Hamilton, S.R., H. Li, H. Wischnewski, A. Prasad, J.S. Kerley-Hamilton, T. Mitchell, A.J. Walling, R.C. Davidson, S. Wildt, and T.U. Gerngross. Intact {alpha}-1,2-endomannosidase is a typical type II membrane protein. Glycobiology. 15(6):615-24 (2005)
- Wildt, S., and T.U. Gerngross. The humanization of N-glycosylation pathways in yeast. Nature Reviews Microbiol. 3(2):119-28 (2005)
- Gerngross, T.U., Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nature-Biotechnology, 1409 -1414 (2004)
- Hamilton, S.R., P. Bobrowicz, B. Bobrowicz, H. Li, T. Mitchell, J.H. Nett, S. Rausch, T.A. Stadheim, S. Wildt, H. Wischnewski, and T.U. Gerngross. Production of complex human glycoproteins in yeast. Science, 301, 1244 (2003) (Abstract, Full Text Version)
Patents
- Medical device comprising polyhydroxyalkanoate having pyrogen removed using oxidizing agent | 8771720
- Method of forming medical devices having pyrogen removed for in vivo application | 8231889
- Medical device comprising polyhydroxyalkanoate having pyrogen removed | 7906135
- ARG1, ARG2, ARG3, HIS1, HIS2, HIS5, HIS6 genes and methods for stable genetic integration | 7479389
- Method for making devices using polyhydroxyalkanoate having pyrogen removed | 7244442
Courses
- ENGS 35: Biotechnology and Biochemical Engineering
News
In the News
The Boston Globe
In the Long War Against COVID, This Waltham Biotech is Designing a Way to Fight All Variants
Dec 06, 2021
In the Long War Against COVID, This Waltham Biotech is Designing a Way to Fight All Variants
Dec 06, 2021
Fierce Biotech
Gerngross Biotech Ankyra Therapeutics Nabs $45M Series B to Jump into the Clinic, Hires New CMO
Nov 16, 2021
Gerngross Biotech Ankyra Therapeutics Nabs $45M Series B to Jump into the Clinic, Hires New CMO
Nov 16, 2021
The Boston Globe
Adagio Files for IPO, Sees Need for COVID Treatments for ‘Years to Come’
Jul 19, 2021
Adagio Files for IPO, Sees Need for COVID Treatments for ‘Years to Come’
Jul 19, 2021
Valley News
Investors Think Lebanon Biotech Startup May Be a Winner in the Fight Against the Coronavirus
Aug 31, 2020
Investors Think Lebanon Biotech Startup May Be a Winner in the Fight Against the Coronavirus
Aug 31, 2020
The Boston Globe
Waltham Startup Focuses on Engineering Antibodies As a Bridge to COVID-19 Vaccine
Jul 16, 2020
Waltham Startup Focuses on Engineering Antibodies As a Bridge to COVID-19 Vaccine
Jul 16, 2020
New Hampshire Public Radio
Getting By, Getting Ahead: Start-Up Entrepreneur Brings High-Tech Talent To Rural N.H.
Jul 11, 2012
Getting By, Getting Ahead: Start-Up Entrepreneur Brings High-Tech Talent To Rural N.H.
Jul 11, 2012
Xconomy
Biotech Vet Gerngross Dishes Out More Details On Latest VC-Backed Startup Arsanis
Jul 29, 2011
Biotech Vet Gerngross Dishes Out More Details On Latest VC-Backed Startup Arsanis
Jul 29, 2011
Scientific American
The 2004 Scientific American 50 Award: Business Leaders recognizes GlycoFi
Mar 07, 2011
The 2004 Scientific American 50 Award: Business Leaders recognizes GlycoFi
Mar 07, 2011
Chemical & Engineering News
Glycosylation Engineering; Controlling Personalities Tame Wild Sugars on Proteins
Mar 07, 2011
Glycosylation Engineering; Controlling Personalities Tame Wild Sugars on Proteins
Mar 07, 2011
Chemical & Engineering News
Adimab believes its yeast-based antibody discovery system could change how biotherapeutics are found
Mar 07, 2011
Adimab believes its yeast-based antibody discovery system could change how biotherapeutics are found
Mar 07, 2011